Sahajanand Medical Technologies IPO (₹327-344): the company gets none of the ₹475 crore, FY26 profit is ₹69 crore, but cash flow turned negative in the June quarter. Should you subscribe?
Sahajanand Medical Technologies, the Surat-based maker of heart stents, wants ₹475 crore in its IPO, and not one rupee of it goes to the company. Every share is sold by existing investors and the promoter family. At ₹344 the stock is priced at about 53 times FY26 earnings. Is that fair for a business whose cash flow turned negative in the latest quarter?
Sahajanand Medical Technologies - Price band: ₹327-344 per share. Issue open 15-19 October, listing on BSE and NSE expected 23 October. - Market cap at ₹344: about ₹3,497 crore (10.16 crore shares). The IPO creates no new shares, so this value is the same before and after the issue. - P/E at ₹344: about 53 times FY26 diluted earnings of ₹6.48. On the April-June 2026 quarter multiplied by four (my own simple estimate), it is about 59 times. - Peers named in the offer document: Poly Medicure 51.4 times and Laxmi Dental 36.4 times (as reported from the document, 6 October 2026 prices). - Market cap to FY26 revenue: about 2.9 times.
The final subscription numbers and the listing price are not known yet, because the issue is still open until 19 October. Any GMP you see online (reported at about ₹43-47 in mid-October) is unofficial and can disappear.
The anchor book: ₹140 crore from funds
On 14 October, the day before the issue opened, the company allotted 40.72 lakh shares to anchor investors at ₹344. That raised ₹140.06 crore, about 29.5% of the issue.
- Named in reports: Nippon India Mutual Fund, DSP Mutual Fund and WhiteOak Capital Mutual Fund. Some reports also name Invesco India, UTI, Allianz Global Investors, Natixis, and Tata AIA Life. The lists differ from site to site, and I could not find the amount each investor took. - Lock-in: half of the anchor shares are locked for 30 days and half for 90 days. If counted from the 14 October allotment date, that is about mid-November and mid-January. The exact dates are not confirmed. - The anchor book is a decent signal of fund interest, but it is smaller than the ₹759 crore Bonfiglioli raised on the same day.
What the company does
The company says it is incorporated in Gujarat in 2001 (the year in its company registration number). Its head office is in Surat, with a corporate office in Mumbai. It makes medical devices for the heart. It has two main groups:
- Vascular intervention (VI): coronary stents and balloons. This is 61% of FY26 revenue. - Structural heart (SH): TAVI heart valves and occluders. This is 17% of revenue and grew from 12% in FY24. - Others, mostly traded goods plus its own renal stents and drug-coated balloons: 22%.
It has three factories: two in India and one in Thailand. It sold in 77 countries in FY26. India is now only 24% of revenue; Europe is 38% and the rest of the world is 38%.
The industry is growing steadily. The offer document, quoting a Frost & Sullivan report, says the global heart-device market was about US$26.3 billion in 2025 and may reach US$37.8 billion by 2030, a growth rate of 7.5% a year.
Results: profit has turned, but one product carries the business
₹ crore FY24 FY25 FY26 Apr-Jun 2026 --------------- Revenue from operations 902 1,025 1,210 352 EBITDA 110 128 171 49 EBITDA margin 12.2% 12.5% 14.1% 13.8% Profit after tax -7 25 69 15 Return on equity -2.3% 3.7% 10.4% 2.1% (3 months) Return on capital employed 8.1% 10.4% 11.6% 3.2% (3 months)
- Revenue grew 34% in two years. Profit went from a loss of ₹7 crore to ₹69 crore. - One report says FY26 profit includes a tax write-back of about ₹8.7 crore. Without it, the P/E would be nearer 62 times. I could not check this in the filing summary, so treat it as a report. - One stent brand, Supraflex Cruz, gave 37% of FY26 revenue (48% in FY24). The offer document lists this concentration as a top risk. - Capacity use in FY26: stents 78%, catheters 92%, TAVI valves 20%, occluders 35%. So the stent lines are nearly full, while the newer structural-heart lines have room.
Cash flow, receivables and borrowings
- Cash from operations was ₹41 crore, ₹74 crore and ₹105 crore in FY24, FY25 and FY26, above profit each year. But in April-June 2026 it was minus ₹22 crore while profit was ₹15 crore. - Net working capital stood at 138 days of revenue in FY26 (144 days in FY25 and FY24). That means cash stays tied up in stock and unpaid bills for more than four months.
- Trade receivables (money customers owe the company): data sites reporting the offer document show about ₹215 crore, ₹263 crore and ₹286 crore at March 2024, 2025 and 2026, and ₹307 crore at June 2026. That is about 24% of FY26 revenue. The same reports say about ₹49 crore is doubtful and ₹28 crore has been due for more than three years. The filing summary I read does not show these lines, so check them in the full document. - Borrowings (money the company owes lenders) have risen from ₹175 crore in March 2024 to ₹321 crore in June 2026. Net debt was 1.1 times FY26 EBITDA.
- Fixed assets: the offer-document summary gives no total. Its gross fixed asset turnover is 3.4 times, which shows the plants earn about ₹3.4 of revenue for every ₹1 of equipment at cost.
Who is selling, and at what cost
The issue is 1.38 crore shares, 13.6% of the company. The sellers:
Seller Type Shares (lakh) Cost per share At ₹344 --------------- Samara Capital Investor 64.8 ₹46.4 7.4x Shree Hari Trust Promoter family trust 27.0 ₹13.5 26x Dhirajkumar Vasoya Promoter group 20.0 ₹0.63 n/a NHPEA Sparkle (linked to Morgan Stanley Private Equity Asia, per press reports) Investor 13.4 ₹97.6 3.5x Kotak Pre-IPO Opportunities Fund Investor 13.1 ₹262.5 1.3x
- The promoter family trust and Mr Vasoya sell about ₹162 crore. After the sale, the promoters and promoter group still hold about 36%. - Kotak's pre-IPO fund paid ₹262 and gets about ₹344, a gain of 31%. That tells you recent investors have not made large gains at this price. Across the last year, the average price paid for shares was ₹238, and the highest was ₹395, above the top of this price band. - Ashish Kacholia holds 10.96 lakh shares (1.08%) and is not selling. The offer document lists Alchemy Capital with 0.40% and an RBA Finance entity with 1.08% too. A report says some of these pre-IPO buys were at ₹365 in 2025, but I could not confirm the price in the filing. - The company's chairperson, Jose Calle Gordo, and a board member who represents Samara Capital sit on the board. The managing director and CEO, Bhargav Kotadia (36, studied at Purdue University, USA), is a promoter. His father, Dhirajlal Kotadia (68), is chairman emeritus.
Price compared with peers
The offer document names two listed peers.
Company P/E (FY26 earnings) ------ Laxmi Dental 36.4x Poly Medicure 51.4x Sahajanand at ₹344 53.1x
Poly Medicure is a broad maker of disposable medical products, and Laxmi Dental is a dental-aligner company. Neither makes heart stents, so the peer set is a loose fit. India has few listed pure-play heart-device makers.
Risks the company lists
- Rules. Rules for medical devices and any action by a regulator can stop sales. Stent prices in India are also capped by the government. - Concentration. One stent brand gives over a third of revenue. Vascular products give 61%. - Suppliers. The top 10 suppliers gave 59% of purchases in FY26, and some parts come from a single source. - Cases. There are 98 tax cases against the company, with the total amount (including other cases) about ₹132 crore. - Currency. Three-quarters of revenue is earned outside India. - Cash. Cash flow was negative in the latest quarter and borrowings keep rising.
The one thing to remember At ₹344 the stock costs 53 times FY26 profit, and about 59 times on the latest quarter. For that price, the company has to keep growing profit at a strong pace, and fix its cash flow.
So, should you subscribe?
It is your call. These are the points to weigh:
- For: fast growth, a margin that is rising, a real research business, and mutual funds in the anchor book. - Against: no money comes to the company, the price is above its closest peer, one product dominates, and cash has gone negative.
The final price depends on demand. Read the full offer document before you bid.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.sebi.gov.in/sebidata/commondocs/oct-2026/Sahajanand%20Medical%20technologies%20LimitedDAp.pdf - https://www.chittorgarh.com/news-detail/ipo/confirmed-ipo/sahajanand-medical-technologies-ipo/11028/ - https://hdfcsky.com/news/sahajanand-medical-technologies-garners-rs-140-cr-from-anchor-investors-ahead-of-ipo - https://deathgamersolo.substack.com/p/sahajanand-medical-technologies-ipo - https://mpulseindia.substack.com/p/four-ipos-open-on-15-october-strengths - https://www.indmoney.com/blog/ipo/why-sahajanand-medical-ipo-profits-are-rising - https://www.ipopremium.in/view/ipo/1409/sahajanand-medical-technologies-ltd